Clinical and laboratory assessment of the efficacy of baclofen (Lioresal) on urethral sphincter spasticity in patients with traumatic paraplegia.
A comparative clinical trial with oral and intravenous baclofen (Lioresal) was performed in a homogeneous group of 70 male patients, hospitalized with traumatic paraplegia. The dosage was 75 mg daily by mouth over a period of 10 days or 20 mg daily i.v. for 2 days. Drug efficacy was evaluated both clinically (residual urine; facilitation of micturition) and urodynamically (integrated cystosphincterometry, sphincter electromyography and micturition cysto-urethrograms). During oral therapy there were no significant changes in any of the studied parameters. Intravenous administration, on the contrary, proved highly effective and better tolerated.
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000613:Aminobutyrates / Q000627:therapeutic use*; D001418:Baclofen / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D004361:Drug Tolerance; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D010264:Paraplegia / Q000150:complications* / Q000209:etiology; D014521:Urethra / Q000187:drug effects* / Q000294:innervation; D001750:Urinary Bladder, Neurogenic / Q000188:drug therapy*; D014947:Wounds and Injuries / Q000150:complications
D000613:Aminobutyrates; D001418:Baclofen